Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol

Abstract

Introduction:

Chronic inflammatory diseases (CIDs), including rheumatic diseases and other inflammatory conditions, often affect women of reproductive age. Tumor necrosis factor inhibitors (TNFi) are widely used to treat CID, but there is limited information on outcomes of TNFi-exposed pregnancies. We evaluated pregnancy outcomes from 1392 prospectively reported pregnancies exposed to certolizumab pegol (CZP), a PEGylated, Fc-free TNFi with no to minimal placental transfer.

Methods:

CZP-exposed pregnancies in patients with CID from the UCB Pharmacovigilance global safety database were reviewed from the start of CZP clinical development (July 2001) to 1 November 2020. To limit bias, the analysis focused on prospectively reported cases with known pregnancy outcomes.

Results:

In total, 1392 prospective pregnancies with maternal CZP exposure and known pregnancy outcomes (n = 1425) were reported; 1021 had at least first-trimester CZP exposure. Live birth was reported in 1259/1425 (88.4%) of all prospective outcomes. There were 150/1425 (10.5%) pregnancy losses before 20 weeks (miscarriage/induced abortion), 11/1425 (0.8%) stillbirths, and 5/1392 (0.4%) ectopic pregnancies. Congenital malformations were present in 30/1259 (2.4%) live-born infants, of which 26 (2.1%) were considered major according to the Metropolitan Atlanta Congenital Defects Program criteria. There was no pattern of congenital malformations.

Discussion and conclusion:

No signal for adverse pregnancy outcomes or congenital malformations was observed in CZP-exposed pregnancies. Although the limitations of data collected through this methodology (including underreporting, missing information, and absence of a comparator group) should be considered, these data provide reassurance for women with CID who require CZP treatment during pregnancy, and their treating physicians.

Keywords

certolizumab pegol congenital malformation infant miscarriage pregnancies preterm birth TNFi

Graphical Summary

Introduction

Chronic inflammatory diseases (CIDs), including rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), Crohn’s disease (CD), and psoriasis (PSO), often affect women of reproductive age. Many of these diseases manifest in early adulthood, meaning disease activity often overlaps with peak reproductive years for women.^1,2 There is evidence that uncontrolled disease activity in CID during pregnancy can increase the rate of adverse pregnancy outcomes such as miscarriage, preterm delivery, and low birth weight; therefore, these pregnancies may be considered higher risk when left untreated.^3–12 Careful management of women with CID who are pregnant, potentially pregnant, or planning pregnancy at initiation of a pharmacological treatment is therefore crucial, including ensuring patients reach a stable condition with low inflammatory activity prior to pregnancy. Moreover, because many pregnancies are unplanned, reproductive health and potential for pregnancy should be discussed with women of childbearing age with CID early in the course of disease.^13,14

Some medications commonly used to treat rheumatic disease, including corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), methotrexate, and opioids, have been associated with adverse pregnancy outcomes,^15–19 resulting in a need to reduce their intake during pregnancy. In line with current treatment guidelines,^14,20–22 tumor necrosis factor inhibitors (TNFi) are widely used to treat CIDs, and currently available data suggest their use is compatible with the first trimester of pregnancy, when organogenesis occurs, and for some TNFi, the second and third trimesters.^12,20 Evidence is sufficient to indicate that certolizumab pegol (CZP) can be continued for the entire duration of pregnancy in women with rheumatic disease, though some guidelines suggest stopping other TNFi, including etanercept, adalimumab, and infliximab in the weeks or months prior to delivery to decrease fetal exposure.^14,20,23 Given this changing treatment landscape for CID in pregnancy, it is important health care providers have access to all available information to enable individual decision making in women of childbearing age, and ensure the benefits and risks of biologic therapies are appropriately understood.

Currently, most evidence on pregnancy outcomes following exposure to biologics comes from observational and cross-sectional studies.²⁴ However, prospective/retrospective registries, real-world evidence, and pharmacovigilance databases may provide additional evidence in biologic-treated women during pregnancy.

CZP is a PEGylated, Fc-free TNFi established for the treatment of several inflammatory diseases, including RA, axSpA, PsA, CD, and PSO.^25,26 Unlike other TNFi, CZP lacks an Fc fragment and thus does not bind the neonatal Fc receptor, which mediates maternal–fetal transfer of antibodies from the first trimester onward.^27,28 Clinical pharmacokinetic studies showed that CZP had no to minimal levels of placental transfer during the third trimester;^29,30 continued CZP use is therefore considered to be compatible with pregnancy in women with a CID if clinically needed.^25,26 Furthermore, when prescribed postpartum, it has been shown to have minimal transfer from plasma to breast milk.³¹

Data on pregnancies exposed to CZP from UCB’s Pharmacovigilance global safety database, using cutoff dates in 2014 and 2017, have been previously reported, with 528 prospective pregnancies with known outcomes reported up to 2017.^32,33 These reports showed no increase in adverse outcomes in CZP-exposed prospective pregnancies, compared with the general population. Here, we report data up to November 2020 from 1392 prospective pregnancies with known outcomes and CZP exposure from the UCB Pharmacovigilance global safety database, including 1021 with first-trimester CZP exposure. Data collected include rates of adverse maternal/fetal outcomes, congenital malformations, as well as preterm delivery and birth weight. Pregnancy outcomes across different indications for CZP treatment are broken down for further review. In addition, confounding factors potentially contributing to adverse pregnancy outcomes in severe CID patients treated with CZP are evaluated.

Methods

Data source and patient populations

The methodology used to collect pregnancy data has been previously reported.³³ Details of pregnancies with CZP exposure were obtained from the UCB Pharmacovigilance global safety database from the start of CZP clinical development (earliest report 12 July 2001) up to a cutoff date of 1 November 2020. Data were obtained from spontaneous reports (information received directly from the patient or health care provider), or from interventional and non-interventional studies (including non-pregnancy registry studies). Organization of Teratology Information Specialists (OTIS) case reports were excluded, since they were collected as part of an ongoing prospective pregnancy registry (NCT01797224).

Pregnancy outcomes were collected for prospective and retrospective pregnancies with CZP exposure. A prospective pregnancy is one in which CZP exposure was reported to UCB Pharma prior to knowledge of the pregnancy outcome or prior to detection of a congenital malformation on prenatal examination. A retrospective pregnancy is one in which CZP exposure was reported to UCB Pharma after the outcome of the pregnancy was known or after detection of a congenital malformation on prenatal test. To limit potential reporting bias associated with retrospective cases, here we focus on outcomes from prospectively reported pregnancies with maternal CZP exposure up to the cutoff date, including those previously published.^32,33

Pregnancy outcomes

Pregnancy outcomes were descriptively reported and included live birth, ectopic pregnancy, pregnancy loss before 20 weeks of gestation due to miscarriage (non-induced embryonic/fetal death before 20 weeks’ gestation) or induced abortion (medically indicated or elective), stillbirth (fetal death occurring at or after 20 weeks’ gestation), and congenital malformations. For live births, we analyzed the following outcomes: congenital malformations, preterm delivery (delivery before 37 weeks’ gestation), preterm delivery according to reported maternal corticosteroid use, and low birth weight (<2500 g).^34,35 Where both birth weight and gestational age at delivery were recorded, the percentage of live-born infants with low birth weight who were small-for-gestational age (SGA; birth weight <10th centile³⁶) was calculated.

Pregnancies with unknown outcomes included ongoing pregnancies and those with no pregnancy outcome reported; these pregnancies were not included in the analysis.

Timing of CZP exposure during pregnancy was recorded by trimester, defined based on the first day of the last menstrual period. The first trimester was defined as the period up to 12 weeks and 6 days’ gestation, the second as 13–28 weeks and 6 days’ gestation, and the third as any time at or after 29 weeks’ gestation. If no information on timing of CZP exposure during pregnancy was available, this was reported as ‘unknown’ in the safety database. Also collected in the database were maternal indication(s) for CZP treatment, maternal age at the start of pregnancy, maternal comorbidities (gestational diabetes, hypertensive disease of pregnancy, infections during pregnancy, and postpartum), country of origin, and concomitant medications.

Cases of congenital malformations were reviewed by an external clinical teratologist and classified as major or minor using the Metropolitan Atlanta Congenital Defects Program (MACDP)³⁷ and the European Surveillance of Congenital Anomalies (EUROCAT) criteria.³⁸

Analysis of variables associated with pregnancy outcomes

A univariate logistic regression analysis was used to identify baseline variables associated with pregnancy loss at <20 weeks’ gestation, preterm birth, and low birth weight. The following baseline variables (yes/no unless otherwise stated) were included: maternal age (⩽35 or >35 years); CZP indication: RA, PsA, axSpA, CD, and PSO; gestational diabetes; hypertensive disease of pregnancy (including hypertension, preeclampsia, and eclampsia); maternal infections; and any use of the following drugs during pregnancy: systemic corticosteroids excluding topical and inhaled preparations, NSAIDs, opioid analgesics, and methotrexate/leflunomide. Dexamethasone use, recorded in three cases, was not excluded from the model because the indication for its prescription was not reported. Each variable also included an ‘unknown’ category to account for missing information not reported in the safety database. All of these variables, if present in at least 10% of the CZP-exposed population, were entered into a multivariable stepwise regression model. The multivariable model used a forward selection criterion of p < 0.05 and a backward elimination criterion of p ⩾ 0.1. Given the heterogeneity and sparsity of the information reported, it was not possible to include dose and time of exposure of concomitant medications in either the univariate or multivariable analysis.

Outcomes from the univariate and multivariable analyses are reported as odds ratios (ORs) with 95% confidence intervals (CIs).

A checklist for the reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) is provided in the supplementary material (Supplementary Table 1).³⁹

Patient and public involvement

Neither patients nor other members of the public were involved in the design, conduct, reporting, or dissemination of this research.

Results

Patient disposition and baseline characteristics

A total of 5681 reports of pregnancies (including both prospective and retrospective cases) with CZP exposure were identified in the UCB Pharmacovigilance global safety database from the start of CZP clinical development up to the cutoff date of 1 November 2020, from all reporting sources, as described above. Of these, 5576/5681 (98.2%) and 105/5681 (1.8%) had maternal and paternal CZP exposure, respectively (Figure 1).

Figure 1.

Reports of pregnancies exposed to CZP identified in the UCB Pharmacovigilance global safety database.

Of all 4234 reported prospective pregnancies, 1392 (32.9%) had known outcomes (n = 1425 pregnancy outcomes; see Figure 1 and Table 1). Of these pregnancies, the most common indication for CZP treatment was RA (n = 643), followed by CD (n = 293), axSpA (n = 215), PsA (n = 113), PSO (n = 61), and other (n = 52); diagnosis data were missing in 60 patients; some patients had multiple indications.

Table 1.

Demographics and baseline characteristics of prospective pregnancies with maternal CZP exposure.

% (n),^a unless otherwise specified	Known pregnancy outcome														Unknown pregnancy outcome
% (n),^a unless otherwise specified	All patients^b		Patients with RA		Patients with axSpA		Patients with PsA		Patients with CD		Patients with PSO		Other^c		Ongoing pregnancies		Not reported
Number of pregnancies	1392		643		215		113		293		61		52		594		2248
Number of pregnancy outcomes	1425		652		222		119		299		61		52		599^d		2267^d
Report source
Spontaneous reports	41.5	(577)	43.1	(277)	37.2	(80)	33.6	(38)	36.9	(108)	21.3	(13)	65.4	(34)	48.5	(288)	46.4	(1043)
Clinical trials	6.5	(91)	5.1	(33)	6.0	(13)	1.8	(2)	9.6	(28)	13.1	(8)	9.6	(5)	0.2	(1)	0.4	(9)
NIS/registries/other	52.0	(724)	51.8	(333)	56.7	(122)	64.6	(73)	53.6	(157)	65.6	(40)	25.0	(13)	51.3	(305)	53.2	(1196)
Type of birth
Singleton	97.7	(1360)	98.6	(634)	96.7	(208)	95.6	(108)	98.0	(287)	100.0	(61)	100.0	(52)	99.3	(590)	99.2	(2231)
Multiple	2.3	(32)	1.4	(9)	3.3	(7)	4.4	(5)	2.0	(6)	0	(0)	0	(0)	0.7	(4)	0.8	(17)
Region
North America	47.3	(658)	36.1	(232)	33.5	(72)	47.8	(54)	86.7	(254)	62.3	(38)	28.8	(15)	39.9	(237)	42.3	(950)
South America	2.9	(41)	4.4	(28)	4.2	(9)	0.0	(0)	1.4	(4)	0.0	(0)	0	(0)	6.9	(41)	2.3	(52)
Western Europe	26.1	(363)	24.0	(154)	40.0	(86)	38.9	(44)	6.8	(20)	32.8	(20)	48.1	(25)	18.2	(108)	42.3	(952)
Central/Eastern Europe	3.3	(46)	3.3	(21)	5.6	(12)	0.9	(1)	3.1	(9)	3.3	(2)	1.9	(1)	1.9	(11)	1.7	(38)
Asia/Australia	20.3	(282)	32.3	(208)	16.7	(36)	12.4	(14)	1.4	(4)	1.6	(1)	21.2	(11)	33.2	(197)	11.4	(256)
Africa	0.1	(2)	0	(0)	0	(0)	0	(0)	0.7	(2)	0	(0)	0	(0)	0	(0)	0	(0)
Maternal age (years), mean (SD)	31.9	(5.1)	32.8	(5.1)	31.6	(4.6)	31.9	(4.6)	30.3	(4.8)	32.2	(4.6)	29.2	(5.4)	31.6	(5.1)	31.9	(6.0)
Maternal age categories
<18 years	0.1	(2)	0	(0)	0	(0)	0	(0)	0.3	(1)	0	(0)	1.9	(1)	0	(0)	0.1	(3)
⩾18 to ⩽35 years	63.4	(883)	59.4	(382)	62.3	(134)	62.8	(71)	78.2	(229)	68.9	(42)	61.5	(32)	55.1	(327)	33.7	(757)
>35 years	21.9	(305)	28.3	(182)	18.6	(40)	20.4	(23)	13.7	(40)	21.3	(13)	11.5	(6)	15.0	(89)	10.3	(231)
Missing	14.5	(202)	12.3	(79)	19.1	(41)	16.8	(19)	7.8	(23)	9.8	(6)	25.0	(13)	30.0	(178)	55.9	(1257)
CZP exposure
Preconception only	1.2	(17)	0.8	(5)	0	(0)	0	(0)	3.1	(9)	1.6	(1)	0	(0)	0.7	(4)	0.8	(19)
At least first trimester	73.3	(1021)	76.5	(492)	65.1	(140)	70.8	(80)	79.9	(234)	67.2	(41)	71.2	(37)	56.1	(333)	48.1	(1082)
All trimesters	39.3	(547)	40.6	(261)	38.6	(83)	38.1	(43)	45.7	(134)	26.2	(16)	32.7	(17)	4.5	(27)	5.9	(132)
Other	22.5	(313)	21.2	(136)	33.5	(72)	26.5	(30)	11.3	(33)	26.2	(16)	26.9	(14)	24.1	(143)	18.9	(425)
Missing	2.9	(41)	1.6	(10)	1.4	(3)	2.7	(3)	5.8	(17)	4.9	(3)	1.9	(1)	19.2	(114)	32.1	(722)
Maternal comorbidities
Gestational diabetes	2.7	(37)	2.2	(14)	3.7	(8)	3.5	(4)	0.7	(2)	8.2	(5)	7.7	(4)	0.3	(2)	0.5	(11)
Hypertensive disease of pregnancy	2.8	(39)	3.7	(24)	1.4	(3)	6.2	(7)	1.4	(4)	1.6	(1)	3.8	(2)	0.2	(1)	0.3	(7)
Maternal infections^e	11.6	(162)	11.8	(76)	16.7	(36)	21.2	(24)	7.5	(22)	14.8	(9)	11.5	(6)	3.5	(21)	5.4	(121)
Available data on concomitant medications^f	786		380		91		42		223		26		35		89		389
Corticosteroids^g	34.0	(267)	45.5	(173)	18.7	(17)	14.3	(6)	26.5	(59)	7.7	(2)	42.9	(15)	23.6	(21)	21.6	(84)
NSAIDs	14.9	(117)	16.6	(63)	29.7	(27)	14.3	(6)	6.7	(15)	11.5	(3)	14.3	(5)	14.6	(13)	7.2	(28)
Methotrexate	10.2	(80)	16.6	(63)	2.2	(2)	7.1	(3)	3.6	(8)	0	(0)	14.3	(5)	5.6	(5)	9.0	(35)
Leflunomide	0.4	(3)	0.3	(1)	0	(0)	0	(0)	0.4	(1)	0	(0)	2.9	(1)	1.1	(1)	1.8	(7)
Azathioprine	9.9	(78)	1.1	(4)	2.2	(2)	0	(0)	32.3	(72)	0	(0)	0	(0)	1.1	(1)	6.2	(24)
Sulfasalazine	13.4	(105)	18.9	(72)	9.9	(9)	9.5	(4)	5.8	(13)	0	(0)	11.4	(4)	7.9	(7)	14.7	(57)
Opioid analgesics	8.7	(68)	5.3	(20)	12.1	(11)	2.4	(1)	14.3	(32)	3.8	(1)	14.3	(5)	1.1	(1)	5.4	(21)

axSpA, axial spondyloarthritis; CD, Crohn’s disease; CZP, certolizumab pegol; NIS, non-interventional studies; NSAIDs, nonsteroidal anti-inflammatory drugs; PsA, psoriatic arthritis; PSO, psoriasis; RA, rheumatoid arthritis; SD, standard deviation.

All percentages are calculated using the number of pregnancies as the denominator.

Includes patients with ‘missing’ indication.

Includes off-label indications for CZP use; the most frequent ‘other’ indications were juvenile idiopathic arthritis, ulcerative colitis, antiphospholipid syndrome, Behcet’s syndrome, and seronegative arthritis.

Inferred number of pregnancy outcomes based on the available data and count.

The most frequent maternal infections were upper respiratory tract (3.8%), viral (2.7%), urogenital (2.4%), and lower respiratory tract (1.5%) infections.

Percentages reported are for any use during pregnancy in patients with available information on concomitant medication intake. Due to the sparsity of the information, dose and time of exposure is not included.

Systemic corticosteroids included prednisone (42.5% of total systemic corticosteroids), prednisolone (41.5%), and methylprednisolone (9.8%); dexamethasone use was recorded in three cases.The bold typeface indicates percentages of patients. The numbers in parenthesis indicate the n number of patients, as shown in the heading at the top left of the table where it says “% (n), unless otherwise specified.

Prospective pregnancies with known outcomes

Maternal demographics

In total, 577/1392 (41.5%) records of prospective pregnancies with maternal CZP exposure were obtained from spontaneous reports and 91/1392 (6.5%) from clinical trials. The remaining 724/1392 (52.0%) came from non-interventional studies, including non-pregnancy registry data or other sources. Most reports originated from patients based in North America (658/1392; 47.3%) or Western Europe (363/1392; 26.1%) (Table 1). The mean maternal age was 31.9 years, with most patients (883/1392; 63.4%) aged ⩾18 to ⩽35 years. The mean maternal age across indications was comparable, ranging from 29.2 to 32.8 years. Most prospective pregnancies (1021/1392; 73.3%) were exposed to CZP at least during the first trimester of the pregnancy; 547/1392 (39.3%) were exposed to CZP during all trimesters. Where information was available, maternal comorbidities and concomitant medication intake, including corticosteroids, NSAIDs, methotrexate, leflunomide, azathioprine, sulfasalazine, and opioid analgesics, are reported (Table 1). Baseline characteristics of pregnancies with unknown outcomes were comparable to pregnancies with known outcomes (Table 1).

Pregnancy outcomes

The 1392 pregnancies with 1425 known pregnancy outcomes resulted in 1259/1425 (88.4%) live births (Figure 2). Across all indications, live birth was the most common pregnancy outcome.

Figure 2.

Pregnancy outcomes of prospectively reported pregnancies with maternal CZP exposure.

There were 150/1425 (10.5%) pregnancy losses before 20 weeks’ gestation (Figure 2), including 111/1425 (7.8%) miscarriages and 39/1425 (2.7%) elective or medically indicated abortions. There were 11/1425 (0.8%) stillbirths in total: five occurred in patients with RA and two each in patients with axSpA, PSO, or CD. Ectopic pregnancies were reported in 5/1392 (0.4%) cases: three occurred in patients with RA and one each in women with PSO or CD. In total, 124/1259 (9.8%) live births were preterm and 101/1259 (8.0%) of infants had low birth weight (Table 2). In the overall cohort, quantitative birth weight information plus exact gestational age was only available in 116 live-born infants, precluding estimation of the percentage of SGA infants for the overall cohort.

Table 2.

Adverse outcomes in prospectively reported pregnancies with known pregnancy outcome and maternal CZP exposure.

% (n/N)	All patients		Patients with RA		Patients with axSpA		Patients with PsA		Patients with CD		Patients with PSO		Patients with other indications
Number of pregnancies	1392		643		215		113		293		61		52
Number of pregnancy outcomes	1425		652		222		119		299		61		52
Congenital malformations based on all known pregnancy outcomes	2.5	(35/1425)	2.0	(13/652)	4.1	(9/222)	2.5	(3/119)	2.7	(8/299)	1.6	(1/61)	5.8	(3/52)
Congenital malformations based on live births	2.4	(30/1259)	1.9	(11/582)	4.4	(9/205)	1.8	(2/109)	2.8	(7/253)	2.2	(1/46)	4.4	(2/45)
Pregnancy loss at <20 weeks	10.5	(150/1425)	9.5	(62/652)	6.8	(15/222)	8.4	(10/119)	14.4	(43/299)	19.7	(12/61)	13.5	(7/52)
Miscarriage	7.8	(111/1425)	7.2	(47/652)	4.1	(9/222)	8.4	(10/119)	11.0	(33/299)	14.8	(9/61)	5.8	(3/52)
Elective abortion	2.5	(35/1425)	2.0	(13/652)	2.3	(5/222)	0	(0/119)	3.0	(9/299)	4.9	(3/61)	7.7	(4/52)
Medically indicated abortion	0.3	(4/1425)	0.3	(2/652)	0.5	(1/222)	0	(0/119)	0.3	(1/299)	0	(0/61)	0	(0/52)
Stillbirth	0.8	(11/1425)	0.8	(5/652)	0.9	(2/222)	0	(0/119)	0.7	(2/299)	3.3	(2/61)	0	(0/52)
Ectopic pregnancy^a	0.4	(5/1392)	0.5	(3/643)	0	(0/215)	0	(0/113)	0.3	(1/293)	1.6	(1/61)	0	(0/52)
Preterm delivery based on live births	9.8	(124/1259)	10.7	(62/582)	9.3	(19/205)	11.9	(13/109)	9.5	(24/253)	2.2	(1/46)	4.4	(2/45)
With corticosteroid use	17.8	(44/247)	21.5	(34/158)	6.7	(1/15)	50.0	(3/6)	14.3	(8/56)	0	(0/2)	0	(0/14)
No corticosteroid use	9.5	(44/461)	7.9	(15/191)	17.1	(12/70)	13.2	(5/38)	7.5	(10/133)	0	(0/18)	6.3	(1/16)
Low birth weight^b	8.0	(101/1259)	9.8	(57/582)	5.9	(12/205)	7.3	(8/109)	8.7	(22/253)	2.2	(1/46)	2.2	(1/45)

axSpA, axial spondyloarthritis; CD, Crohn’s disease; CZP, certolizumab pegol; PsA, psoriatic arthritis; PSO, psoriasis; RA, rheumatoid arthritis.

Percentages of ectopic pregnancies are reported using the total number of pregnancies as the denominator.

<2500 g. Both gestational age and birth weight were recorded in 82/101 infants with low birth weight; of these, 54/82 (65.9%) were small-for-gestational age.The numbers in parenthesis indicate the n number of patients, as shown in the heading at the top left of the table where it says “% (n), unless otherwise specified

Congenital malformations

Congenital malformations were reported in 35/1425 known pregnancy outcomes (2.5%), of which 30/1259 presented in live-born infants (2.4%) (Table 2). Of all cases with congenital malformations, 6/35 (17.1%) did not have known first-trimester CZP exposure (unknown exposure in three cases). A total of 26 congenital malformations that presented in 22 live-born infants were classified as major according to the MACDP criteria, representing a prevalence of 2.1% (26/1259) in live-born infants. According to EUROCAT criteria, 17 congenital malformations in 16 live-born infants were major (1.4% (17/1259) of all live births). All five congenital malformations occurring in pregnancies ending in either miscarriage or elective abortion were major according to MACDP criteria (Table 3); according to EUROCAT criteria, only two were major (classification was ‘unknown’ in one case).

Table 3.

Congenital malformations in prospectively reported pregnancies with maternal CZP exposure..

Case	Malformation term	Major according to MACDP criteria	Major according to EUROCAT criteria	Birth outcome	First-trimester exposure	Maternal age	Maternal indication
1	Congenital vericoureteral reflux	Y	N	Live birth	Y	30	CD
2	Club foot	Y	Y	Live birth	Unknown	36	CD
3	Polydactyly	Y	Y	Live birth	Y	43	RA
4	Anal fistula	Y	N	Live birth	Y	32	RA
5	Congenital hydronephrosis	Y	Y	Live birth	N	27	CD
6	Congenital heart disease	Y	N	Live birth	Y	35	RA
7	Cerebral ventricle dilatation	Y	Y	Live birth	N	Unknown	axSpA
8	Pyloric stenosis	Y	N	Live birth	Y	35	axSpA
9	Cleft palate	Y	Y	Live birth	Y	34	CD
10	Atrial septal defect	Y	Y	Live birth	Y	29	RA
	Ventricular septal defect	Y	Y
11	Congenital hydrocephalus	Y	Y	Live birth	Y	27	axSpA
12	Gastrointestinal defect	Y	N	Live birth	Y	33	RA
	Trisomy 21	Y	Y
13	Ventricular septal defect	Y	Y	Live birth	Y	29	Other
14	Exomphalos	Y	Y	Live birth	Y	30	RA
15	Exomphalos	Y	Y	Live birth	Y	29	axSpA
16	Atrial septal defect	Y	Y	Live birth	Y	33	axSpA/other
17	Hypospadias	Y	Y	Live birth	Y	32	PsA
18	Hemangioma	Y	N	Live birth	Y	35	axSpA
19	Congenital hydronephrosis	Y	Y	Live birth	Y	37	PsA/axSpA
20	Trisomy 18	Y	Y	Live birth	Y	28	RA
21	Congenital malformation NOS	Y	N	Miscarriage	Y	34	CD
22	Congenital malformation NOS	Y	N	Miscarriage	Y	36	PsA
23	Congenital malformation NOS	Y	Unknown	Miscarriage	Unknown	Unknown	RA
24	Congenital malformation NOS	Y	Y	Elective abortion	Y	41	RA
25	Trisomy 21	Y	Y	Elective abortion	Y	Unknown	Other
26	Chordee	Y	N	Live birth	Y	36	RA
	Penile torsion	N	N
	VACTERL syndrome (atrial septal defect^a)	Y	Y
27	Cardiac murmur	N	N	Live birth	Y	35	CD
	Congenital scoliosis	Y	N
	Torticollis	Y	N
28	Ankyloglossia congenital	N	N	Live birth	N	29	CD
29	Accessory auricle	N	N	Live birth	Y	32	RA
30	Unilateral cryptorchidism	N	N	Live birth	Y	34	RA
31	Ankyloglossia congenital	N	N	Live birth	Y	34	axSpA
32	Ankyloglossia congenital	N	N	Live birth	Y	36	axSpA
33	Strabismus congenital	N	N	Live birth	Unknown	31	RA
34	Ankyloglossia congenital	N	N	Live birth	Y	Unknown	PSO
35	Developmental hip dysplasia	N	N	Live birth	Y	31	CD

axSpA, axial spondyloarthritis; CD, Crohn’s disease; CZP, certolizumab pegol; EUROCAT, European Surveillance of Congenital Anomalies; MACDP, Metropolitan Atlanta Congenital Defects Program; NOS, not otherwise specified; PsA, psoriatic arthritis; PSO, psoriasis; RA, rheumatoid arthritis; VACTERL, vertebral defects, anal atresia, cardiac defects, tracheo-esophageal fistula, renal anomalies, and limb abnormalities.

Reported as part of VACTERL syndrome.

Factors associated with outcomes in prospective CZP-exposed pregnancies

Results of the initial univariate analyses, performed to evaluate associations between baseline variables and pregnancy outcomes (see ‘Methods’ section), are presented in Supplementary Figure 1.

In the multivariable stepwise regression model, reported corticosteroid use (i.e. any use during pregnancy) was identified as associated with increased odds of preterm birth [OR (95% CI): 2.1 (1.3–3.4), p < 0.005] and low birth weight [OR (95% CI): 1.7 (1.0–2.9), p < 0.05] but decreased odds of pregnancy loss at <20 weeks [OR (95% CI): 0.5 (0.3–0.9), p < 0.05] (Figure 3). Reported NSAID use (i.e. any use during pregnancy) was associated with increased odds of pregnancy loss at <20 weeks [OR (95% CI): 2.2 (1.2–4.0), p < 0.05], as was methotrexate/leflunomide use [OR (95% CI): 3.2 (1.7–6.2), p < 0.0005] (Figure 3). The analysis also identified an association between a diagnosis of CD and pregnancy loss at <20 weeks [OR (95% CI): 2.5 (1.5–4.1), p = 0.0005], and between RA and low birth weight [OR (95% CI): 1.9 (1.1–3.3), p < 0.05] (Figure 3). Finally, maternal infections were associated with increased odds of preterm birth [OR (95% CI): 1.9 (1.1–3.5), p < 0.05] (Figure 3).

Figure 3.

Potential confounders identified as significantly associated with pregnancy outcomes from multivariable stepwise regression analysis.^a

Retrospective pregnancies with known outcomes

Out of 1362 outcomes from 1342 retrospectively reported maternal exposure pregnancies, 1259 had known outcomes, including 1014 (80.5%) live births, 199 (15.8%) miscarriages, 11 (0.9%) medically indicated abortions, 9 (0.7%) elective abortions, 13 (1.0%) stillbirths, and 13 (1.0%) ectopic pregnancies; 71/1014 (7.0%) live births were reported preterm and 43/1014 (4.2%) infants had low birth weight. Congenital malformations were reported in 38 cases out of 1259 (3.0%) outcomes, of which 28 cases out of 1014 (2.8%) outcomes presented in live-born infants.

Discussion

This analysis reports outcomes from the largest pregnancy safety database dedicated to CZP use in patients with CID. Outcomes are reported for 1392 prospective pregnancies with maternal CZP exposure, including 1021 with first-trimester exposure. Over 85% of all prospectively reported pregnancies with CZP exposure and known outcomes resulted in live birth, with no observed increase in adverse outcomes.

In the general population, rates of miscarriage range from 12% to 25%,^40,41 abortion 1% to 20.4%,^42,43 major congenital malformations 2% to 3%,^44,45 preterm birth 12%,⁴⁶ and low birth weight 8.2%.⁴⁶ Rates of adverse pregnancy outcomes reported in this analysis are in keeping with those from the general population,^47–51 those from previous registry studies evaluating biologics in pregnancy in women with CID,^52,53 and also with previous publications from the UCB Pharmacovigilance global safety database reporting prospective pregnancy outcomes using cutoff dates in 2014 (339 pregnancies)³² and 2017 (528 pregnancies).³³

In particular, the rates of major congenital malformations in prospective pregnancies from this database were comparable to those reported in the general population,^44,45 although caution is required in assessing data collected through different methodologies. Nonetheless, no pattern of congenital malformations was identified, and there was no discernible trend between maternal CZP indication and major congenital malformations. According to MACDP criteria,³⁷ 26 major congenital malformations occurred in 1259 live-born infants (2.1%), while by EUROCAT criteria,³⁸ 17 were major (1.4%), highlighting that methodological approaches for classifying abnormalities can impact their reported prevalence. In retrospectively reported maternal exposure pregnancies, rates of congenital malformations (2.8% in live births) and other adverse pregnancy outcomes were of similar magnitude, despite the reporting bias inherently associated with retrospective cases.

Whether in utero exposure to TNFi is associated with increased risk of neonatal infections has been investigated in several studies that used heterogeneous methodological approaches and population cohorts. Recent studies on large cohorts of TNFi-exposed pregnancies from Nordic population databases indicated significantly increased odds of neonatal infections during the first year of life compared with matched standard of care-exposed pregnancies,^54,55 while other studies in pregnant women with inflamatory bowel disease (IBD)^52,56 or RA⁵⁷ found no increased risk of neonatal infection after biologic exposure. Of note, these studies recruited mostly pregnancies exposed to etanercept, infliximab, or adalimumab. While the CZP pharmacovigilance database captures neonatal infection information, insufficient reporting makes it difficult to assess the potential impact of CZP on neonatal infection. CZP has no to minimal placental transfer during the third trimester so might be expected to have a minimal impact on infants, but this cannot be confirmed by the current analysis.

In patients with CID, adverse pregnancy outcomes have been associated with disease activity, increased comorbidity rates, and increased use of medications such as corticosteroids.¹⁵ Although details on maternal disease activity were unavailable, information on concomitant medication and comorbidities was available from the database. Stepwise regression analysis identified maternal infection in pregnancy as associated with preterm birth, a link that is well-established in the literature.^58,59

Current treatment guidelines recommend adoption of strategies to minimize or limit corticosteroid intake during pregnancy.^14,15,20,60 This analysis identified an association between maternal corticosteroid use and preterm birth and low birth weight. While these findings are in keeping with previously published data,^15,60 dose and timing of exposure was only recorded in a small number of cases, and therefore these could not be included in our analysis. In addition, CID activity is not routinely recorded in this registry, so the use of corticosteroids could not be adjusted for this important predictor or preterm birth. Given this, limited conclusions on the impact of corticosteroids on CZP-exposed pregnancy outcomes can be drawn from our data.

Similarly, the current analysis identified an association between NSAID use and pregnancy loss at <20 weeks. There are conflicting results about NSAID use in pregnancy and miscarriage.^20,61,62 A caveat of these analyses is that, as with corticosteroid data, there were limited data available on the dose, duration, or timing of medications, any of which may have an impact on outcomes. For instance, it is possible that NSAIDs were used to manage pain associated with pregnancy loss at <20 weeks; thus, the association could be biased by indication.⁶³

Although this analysis focused on prospective data only, it is constrained by the methodology associated with the spontaneous reporting system and the collection of pharmacovigilance data from a number of heterogeneous sources. Since information is collected through a passive reporting system, it has several inherent limitations, including underreporting, incomplete reporting of information, and missing pregnancy outcome data. Efforts to collect data and increase the number of cases with known pregnancy outcomes will therefore be an important focus for the future. Furthermore, limited information was reported in the database on disease activity during pregnancy or other items that may be of relevance, such as family history, dose and time of exposure to concomitant medication, and definitions used to diagnose comorbidities. The absence of a comparator group (pregnancies in women with CID and no CZP exposure) is a further limitation of these analyses. However, these limitations are mitigated by the large number of outcomes available, which can increase confidence in the conclusions drawn.

To the best of our knowledge, this is one of the largest analyses of pregnancy outcomes with TNFi exposure from a pharmacovigilance database, with outcomes reported from 1392 prospective CZP-exposed pregnancies. Where pregnancy outcomes were known, we found no evidence of increased risk of adverse outcomes or patterns of congenital malformations in pregnancies with maternal CZP exposure compared with the general population. This information is important for women with CID who may have higher risk pregnancies, and will be informative to clinicians and patients in assessing the benefits and risks of their therapeutic decisions before and during pregnancy. Future data from the ongoing prospective OTIS registry study, which will report outcomes from CZP-exposed and non-exposed pregnancies, in addition to continued collection of data in the UCB Pharmacovigilance global safety database, will further add to these findings.

Supplemental Material

sj-doc-2-tab-10.1177_1759720X221087650 – Supplemental material for Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol

Supplemental material, sj-doc-2-tab-10.1177_1759720X221087650 for Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol by Megan Clowse, Rebecca Fischer-Betz, Catherine Nelson-Piercy, Angela E. Scheuerle, Brigitte Stephan, Marla Dubinsky, Thomas Kumke, Rachna Kasliwal, Bernard Lauwerys and Frauke Förger in Therapeutic Advances in Musculoskeletal Disease

Supplemental Material

sj-docx-1-tab-10.1177_1759720X221087650 – Supplemental material for Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol

Supplemental material, sj-docx-1-tab-10.1177_1759720X221087650 for Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol by Megan Clowse, Rebecca Fischer-Betz, Catherine Nelson-Piercy, Angela E. Scheuerle, Brigitte Stephan, Marla Dubinsky, Thomas Kumke, Rachna Kasliwal, Bernard Lauwerys and Frauke Förger in Therapeutic Advances in Musculoskeletal Disease

Footnotes

Acknowledgements

The authors thank the patients and caregivers, the investigators, and their teams who took part in this study. The authors also acknowledge Simone E. Auteri, MSc, EMS, PhD, UCB Pharma, for publication coordination; Maureen Cooney, Tamara Klapka, Laura Shaughnessy, Christine Taeter, and Marie Teil, UCB Pharma, for contributions to analysis and interpretation of the data and critical review; and Jessica Patel, PhD, and Julia Stevens, PhD, from Costello Medical, UK, for medical writing and editorial assistance based on the authors’ input and direction. This study was funded by UCB Pharma.

Author contributions

Megan Clowse: Conceptualization; Investigation; Methodology; Writing – review & editing.

Rebecca Fischer-Betz: Conceptualization; Investigation; Methodology; Writing – review & editing.

Catherine Nelson-Piercy: Conceptualization; Investigation; Methodology; Writing – review & editing.

Angela E. Scheuerle: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.

Brigitte Stephan: Conceptualization; Investigation; Methodology; Writing – review & editing.

Marla Dubinsky: Conceptualization; Investigation; Methodology; Writing – review & editing.

Thomas Kumke: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.

Rachna Kasliwal: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.

Bernard Lauwerys: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.

Frauke Förger: Conceptualization; Formal analysis; Investigation; Methodology; Writing – review & editing.

Conflict of interest statement

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.C.: Consultancy fees from UCB Pharma; grant/research support from GSK, Janssen, and Pfizer. R.F.-B.: Consultancy fees from AbbVie, BMS, Celgene, Chugai, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB Pharma. C.N.-P.: Consultancy fees from Alliance Pharma and UCB Pharma; speakers bureau for Alexion, Janssen, Sanofi, and UCB Pharma. A.E.S.: Consultancy fees for Antiretroviral Pregnancy Registry, Harmony Biosciences, IQVIA, PPD, Sanofi-Genzyme, Syneos, UCB Pharma, and ViiV. B.S.: Lecture fees from AbbVie and UCB Pharma. M.D.: Consultancy fees from AbbVie, Arena, BMS, Celgene, Eli Lilly, Gilead, Janssen, Pfizer, Takeda, and UCB Pharma. T.K.: Employee and shareholder of UCB Pharma. R.K.: Employee and shareholder of UCB Pharma; shareholder of Biogen. B.L.: Employee and shareholder of UCB Pharma. F.F.: Grant/research support from UCB Pharma; speakers bureau for Mepha, Roche, and UCB Pharma.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Jessica Patel, PhD, and Julia Stevens, PhD, from Costello Medical, UK, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines ().

Informed consent

This article reports anonymized case data from a pharmacovigilance safety database. In accordance with Article 9(2)(i) of the General Data Protection Regulation (GDPR),⁶⁴ which recognizes that processing of health data without informed consent is necessary to fulfill pharmacovigilance legislation, informed consent was not required. Routine pharmacovigilance procedures and follow-up are also exempt from data privacy in the United States according to the Health Insurance Portability and Accountability Act of 1996 (HIPAA), Public Law 104-191.⁶⁵

ORCID iD

Megan Clowse

Data sharing

Data from non-interventional studies are outside of UCB’s data sharing policy.

Supplemental material

Supplemental material for this article (including the video abstract) is available online.

References

Kavanaugh

Cush

Ahmed

, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken) 2015; 67(3): 313–325.

Chakravarty

Clowse

Pushparajah

, et al. Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. BMJ Open 2014; 4(2): e004081.

Wallenius

Skomsvoll

Irgens

, et al. Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on first birth. Arthritis Rheum 2011; 63(6): 1534–1542.

Jakobsson

Stephansson

Askling

, et al. Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis 2016; 75(10): 1838–1842.

Mørk

Voss

Möller

, et al. Spondyloarthritis and outcomes in pregnancy and labor: a nationwide register-based cohort study. Arthritis Care Res (Hoboken) 2019; 73(2): 282–288.

Zbinden

van den Brandt

Østensen

, et al. Risk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: disease activity matters. Rheumatology (Oxford) 2018; 57(7): 1235–1242.

Remaeus

Stephansson

Johansson

, et al. Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study. BJOG 2019; 126(10): 1213–1222.

Bröms

Haerskjold

Granath

, et al. Effect of maternal psoriasis on pregnancy and birth outcomes: a population-based cohort study from Denmark and Sweden. Acta Derm Venereol 2018; 98(8): 728–734.

Lima

Janakiraman

Hughes

, et al. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol 2012; 132(1): 85–91.

10.

Lee

Bae

Lee

, et al. Pregnancy outcomes in women with inflammatory bowel disease: a 10-year nationwide population-based cohort study. Aliment Pharmacol Ther 2020; 51(9): 861–869.

11.

Shand

Chen

Selby

, et al. Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes. BJOG 2016; 123(11): 1862–1870.

12.

Kimball

Guenther

Kalia

, et al. Pregnancy outcomes in women with moderate-to-severe psoriasis from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 2021; 157(3): 301–306.

13.

Finer

Zolna

. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med 2016; 374(9): 843–852.

14.

Sammaritano

Bermas

Chakravarty

, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020; 72(4): 529–556.

15.

Palmsten

Bandoli

Vazquez-Benitez

, et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology (Oxford) 2020; 59(6): 1262–1271.

16.

Katz

Waalen

Leach

. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41(3Pt2): S7–S12.

17.

Palmsten

Rolland

Hebert

, et al. Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: daily and cumulative dose. Pharmacoepidemiol Drug Saf 2018; 27(4): 430–438.

18.

Yazdy

Desai

Brogly

. Prescription opioids in pregnancy and birth outcomes: a review of the literature. J Pediatr Genet 2015; 4(2): 56–70.

19.

Nezvalová-Henriksen

Spigset

Nordeng

. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study. BJOG 2013; 120(8): 948–959.

20.

Götestam Skorpen

Hoeltzenbein

Tincani

, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75(5): 795–810.

21.

Flint

Panchal

Hurrell

, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016; 55(9): 1693–1697.

22.

Nast

Smith

Spuls

, et al. EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2020; 34(11): 2461–2498.

23.

Ghalandari

Kemper

Crijns

, et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis 2022; 81: 402–405.

24.

Prieto-Peña

Calderón-Goercke

Adán

, et al. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clin Exp Rheumatol 2021; 39(1): 105–114.

25.

European Medicines Agency. Cimzia summary of product characteristics, 2020, https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf (accessed August 2021).

26.

US Food and Drug Administration (FDA). Label: CIMZIA (certolizumab pegol), 2019, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125160s237lbl.pdf (accessed August 2021).

27.

Simister

. Placental transport of immunoglobulin G. Vaccine 2003; 21(24): 3365–3369.

28.

Catlin

Mitchell

Potchoiba

, et al. Placental transfer of (125)iodinated humanized immunoglobulin G2Δa in the cynomolgus monkey. Birth Defects Res 2020; 112(1): 105–117.

29.

Mariette

Förger

Abraham

, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77(2): 228–233.

30.

Matro

Martin

Wolf

, et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology 2018; 155(3): 696–704.

31.

Clowse

Förger

Hwang

, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 2017; 76(11): 1890–1896.

32.

Clowse

Wolf

Förger

, et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol 2015; 42(12): 2270–2278.

33.

Clowse

MEB

Scheuerle

Chambers

, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol 2018; 70(9): 1399–1407.

34.

World Health Organization (WHO). International statistical classification of diseases and related health problems. tenth revision. 2nd ed. Geneva: WHO, 2004.

35.

World Health Organization (WHO). Born too soon, the global action report on preterm birth. Geneva: WHO, 2012.

36.

Nicolaides

Wright

Syngelaki

, et al. Fetal Medicine Foundation fetal and neonatal population weight charts. Ultrasound Obstet Gynecol 2018; 52(1): 44–51.

37.

Metropolitan Atlanta Congenital Defects Program (MACDP). MACDP: 40th Anniversary edition surveillance report. Birth Defects Res 2007; 79(2): ii–186.

38.

European Surveillance of Congenital Anomalies (EUROCAT). EUROCAT guide 1.4: Instruction for the registration of congenital anomalies, 2013, https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/JRC-EUROCAT-Full-Guide-1-4-version-01-Dec-2020.pdf (accessed August 2021).

39.

Langan

Schmidt

Wing

, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018; 363: k3532.

40.

Regan

Braude

Trembath

. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989; 299(6698): 541–545.

41.

Wang

Chen

Wang

, et al. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril 2003; 79(3): 577–584.

42.

Eurostat. Abortion indicators, 2021, https://ec.europa.eu/eurostat/databrowser/view/demo_fabortind/default/table?lang=en (accessed August 2021).

43.

Kortsmit

Jatlaoui

Mandel

, et al. Abortion surveillance – United States, 2018. MMWR Surveill Summ 2020; 69(7): 1–29.

44.

Centers for Disease Control Prevention (CDC). Update on overall prevalence of major birth defects – Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep 2008; 57(1): 1–5.

45.

European Surveillance of Congenital Anomalies (EUROCAT). Prevalence charts and tables, 2021, https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence_en (accessed August 2021).

46.

Martin

Hamilton

Ventura

, et al. Births: final data for 2010. Natl Vital Stat Rep 2012; 61(1): 1–72.

47.

Ventura

Curtin

Abma

, et al. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. Natl Vital Stat Rep 2012; 60(7): 1–21.

48.

Nybo Andersen

Wohlfahrt

Christens

, et al. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320(7251): 1708–1712.

49.

García-Enguídanos

Calle

Valero

, et al. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol 2002; 102(2): 111–119.

50.

MacDorman

Reddy

Silver

. Trends in stillbirth by gestational age in the United States, 2006-2012. Obstet Gynecol 2015; 126(6): 1146–1150.

51.

Zeitlin

Mortensen

Cuttini

, et al. Declines in stillbirth and neonatal mortality rates in Europe between 2004 and 2010: results from the Euro-Peristat project. J Epidemiol Community Health 2016; 70(6): 609–615.

52.

Mahadevan

Long

Kane

, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 2021; 160(4): 1131–1139.

53.

Chambers

Johnson

, et al. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS ONE 2019; 14(10): e0223603.

54.

Nørgård

Nielsen

Friedman

. In utero exposure to thiopurines/anti-TNF agents and long-term health outcomes during childhood and adolescence in Denmark. Aliment Pharmacol Ther 2020; 52(5): 829–842.

55.

Bröms

Kieler

Ekbom

, et al. Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2020; 52(5): 843–854.

56.

Chaparro

Verreth

Lobaton

, et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol 2018; 113(3): 396–403.

57.

Vinet

Moura

ÉC

Pineau

Abrahamowicz

, et al. Serious infections in rheumatoid arthritis offspring exposed to tumor necrosis factor inhibitors: a cohort study. Arthritis Rheumatol 2018; 70(10): 1565–1571.

58.

Goldenberg

Culhane

Iams

, et al. Epidemiology and causes of preterm birth. Lancet 2008; 371(9606): 75–84.

59.

Cappelletti

Della Bella

Ferrazzi

, et al. Inflammation and preterm birth. J Leukoc Biol 2016; 99(1): 67–78.

60.

Rodriguez

Wang

Ali Khan

, et al. Antenatal corticosteroid therapy (ACT) and size at birth: a population-based analysis using the Finnish medical birth register. PLoS Med 2019; 16(2): e1002746.

61.

Nielsen

Sørensen

Larsen

, et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001; 322(7281): 266–270.

62.

Ferber

Odouli

, et al. Use of nonsteroidal antiinflammatory drugs during pregnancy and the risk of miscarriage. Am J Obstet Gynecol 2018; 219(3): 275.e1–275.e8.

63.

Daniel

Koren

Lunenfeld

, et al. NSAIDs and spontaneous abortions – true effect or an indication bias? Br J Clin Pharmacol 2015; 80(4): 750–754.

64.

General Data Protection Regulation (EU GDPR) Article 9(2)(i), https://gdpr-text.com/read/article-9/ (accessed January 2022).

65.

Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, https://aspe.hhs.gov/report/health-insurance-portability-and-accountability-act-1996 (accessed January 2022).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.12 MB

0.41 MB